Faglioni P, Gasparini M, Spinnler H
Riv Patol Nerv Ment. 1975 Jul-Aug;96(4):270-86.
Twenty-one patients suffering from Parkinson disease were treated with L-Dopa together with an extra-cerebral dopa-decarboxylase inhibitor (Ro4-4602) and with triesyphenidyl. Seven assessments of the patient's clinical condition were carried out over a period of two years with a number of neurological and psychometric tests. At the beginning of the second year of treatment, the signs and symptoms of Parkinson disease began to worsen with an increased disability. In the present paper two possibilities are discussed, namely whether the deterioration was the consequence of L-Dopa administration or whether this was simply the outcome of inadequacy of drug treatment during a period of natural worsening of the disease.
21名帕金森病患者接受了左旋多巴与一种脑外多巴脱羧酶抑制剂(Ro4-4602)以及苯海索联合治疗。在两年时间里,通过一系列神经学和心理测量测试对患者的临床状况进行了7次评估。在治疗的第二年开始时,帕金森病的体征和症状随着残疾程度的增加而开始恶化。在本文中讨论了两种可能性,即病情恶化是左旋多巴给药的结果,还是仅仅是在疾病自然恶化期间药物治疗不足的结果。